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MiR-301a-3p Suppresses Estrogen

Introduction
Breast cancer is the most prevalent type of cancer in women worldwide [1, 2] . Up to 75 % of breast cancer subtypes are estrogen receptor α (ER α) and progesterone receptor (PR) positive. ERα and PR positive tumors are largely well-differentiated, less invasive and are associated with better prognosis in comparison with ERα and PR negative tumors [3] [4] [5] [6] .
ERα is one of the estradiol (E 2 )-activated transcription factors, which regulates a large number of genes connected with proliferation, differentiation and migration [7] and plays a critical role in mammary gland biology and development [8] . E 2 /ERα signaling stimulates proliferation of ERα positive breast cancer cells and it is important for the growth of the primary tumor. Furthermore, the expression of ERα negatively correlates with the progressive grade of invasive ductal breast cancer [9] . Moreover, ERα signaling opposes pathways leading to epithelial to mesenchymal transition (EMT) and cancer stem-like cell phenotype [10, 11] . Thus, expression of ERα is connected with less invasive behavior of breast cancer and is considered to be a good indicator of endocrine therapy and breast cancer survival. This dependency on estrogenic signaling is exploited for treatment with selective estrogen receptor modulators (tamoxifen), selective estrogen receptor down regulators (fulvestrant) or aromatase inhibitors (letrozole) [12, 13] . However, resistance to hormonal therapies connected with transition from hormone-dependent to hormone-independent tumor and metastases formation is the main problem in clinical treatment occurring in almost 40% cases over 10 years of treatment [14, 15] .
Until now, multiple mechanisms have been proposed to explain how breast cancer cells escape dependency on estrogen control and acquire hormone-independent, invasive and resistant phenotype. Among them, epigenetic modulation [16] , transcription regulation [17] , gene mutation [18] and alternative usage of splice variants [19] , posttranslational modifications [20] or microRNA deregulation [21] have been described so far.
MicroRNAs (miRNAs) are small, 22 nucleotides long, non-coding RNAs that negatively regulate gene expression by complementary binding to their target mRNAs, which leads to repression of translation and mRNA degradation [22] . They target a wide spectrum of genes and deregulation of their function has important role in cancer progression [23] . MiR-301a-3p has recently emerged as an oncogenic miRNA whose expression is connected with progression and poor prognosis of pancreatic [24] , gastric [25] , hepatocellular [26] , colorectal [27] and breast cancer [28] .
In this study, we identified ESR1 mRNA as a direct target of miR-301a-3p and we show that overexpression of miR-301a-3p leads to inhibition of estrogenic signaling in ERα positive breast cancer cell lines. Furthermore, our data suggest an important role of miR301a in a shift from estrogen-dependent to estrogen-independent breast cancer and thus in progression of tumor growth.
Materials and Methods
Cell lines and transfections
Human breast cancer cell lines ZR-751, MCF7, T47D and BT474 and non-malignant MCF10A cell line were obtained from American Type Culture Collection and were routinely cultivated in Dulbecco's Modified Eagle Medium (Sigma) supplemented with 10% fetal bovine serum (Thermo Scientific) and 100 U/ml penicillin, 100 µg/ml streptomycin; in 5% CO 2 and 37°C. MCF10A cells were cultivated in DMEM/F12 (Lonza) with 5% horse serum and 100U/ml penicillin, 100 µg/ml streptomycin, supplemented with 0.1 ng/
DNA constructs miR-301a inducible vector
The pri-microRNA-301a sequence was amplified by PCR from cDNA obtained from MCF7 cells using Q5 hot start high-fidelity DNA polymerase (New England BioLabs) with the following primers: Forward 5' CCCTCGTAAAGTCGACTGCATGTTTCTGTTCGAATG; Reverse 5' CAGTTACATTAGATCTGGGCAAGTAACT-GCAGGAAA. The amplified sequence was then cloned into the SalI/BglII sites of pTRE3G-IRES vector (Clontech).
Luciferase vectors
The whole 3'UTR sequence of ESR1 gene was amplified from MCF7 cDNA by using the following primers: Forward 5' TGCAAGTGAGCGGCCGCGAGCTCCCTGGCTCCCACA; Reverse 3' TGCAAGTGAGCGGCCGCTTAGTTTAATTCTTTATTTGAACATC containing the NotI restriction sites. The amplified product was cloned into NotI site of pTK-Cypridina vector (Thermo Scientific). Vectors with deleted first or the second or both sites of predicted miR-301a-3p binding were created by site directed mutagenesis by using Q5 Hot start high-fidelity DNA polymerase (New England BioLabs) according to manufacturer´s protocol with the following primers:
Site 1 Forward 5' TTGTTTTCTAAGTAATTGCTGCCTCTGTCTTTTGAGATTCAAGAAAAATTTC; Site 1 Reverse 5' GAAA-TTTTTCTTGAATCTCAAAAGACAGAGGCAGCAATTACTTAGAAAACAA; Site 2 Forward 5' CATCCCGC-TGGATTCTTTTTCAATGTTTCATTAAACAAAGCAAAGC; Site 2 Reverse 5' GCTTTGCTTTGTTTAATGAAACATTGAAAAAGAATCCAGCGGGATG; the thermal conditions for PCR were: 98°C for 5min; 5 cycles of 98°C for 15s, 80°C for 10 s, 70°C for 30 s and final extension at 72°C for 8 min then 15 cycles of 98°C for 10 s, 80°C for 10 s and 72°C for 8 min followed by final extension at 72°C for 10 min. Then the PCR reaction was incubated with DpnI Fast digest enzyme (Thermo Scientific) at 37°C for 30 min and transformed into TOP10 ultracompetent cells. All constructs were verified by Sanger sequencing (GATC Biotech).
cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (Fermentas) using oligo-dT as primers. qRT-PCR was performed using 5x HOT FIREpol Eva Green qRT-PCR mix (Solis Biodyne). 2.5 µL of cDNA containing 10 ng of template RNA was mixed with 5 µL of master mix (1.5 µL Eva Green mix, 0.197 µL of 10 µM forward and reverse specific primers and 3.3 µL of H 2 O). The thermal profile for qRT-PCR was: 95°C for 12 min, 38 cycles of 95°C for 10 s, 60°C for 20 s and 72°C for 20 s. The sequences of primers used are in Table 1 . The expression of hsa-miR-301a-3p was assessed using the TaqMan MicroRNA Assay (Applied Biosystems, TM000528); snU6 was used for normalization (Applied Biosystems, TM001973). Hsa-miR-301a-3p was transcribed by RevertAid First Strand cDNA Synthesis Kit (Fermentas) using a specific RT primer. One reaction contained: 3.5 µL of RT master mix (1.5 µL 5x reaction buffer, 0.095 µL RNAse inhibitor, 0.75 10 mM dNTPs, 0.5 µL Reverse Transcriptase, 0.655 µL H 2 O), 2.5 µL RNA of 2 ng/ µL concentration and 1.5 µL of oligo-dT primers. Thermal profile was: 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. The subsequent qRT-PCR was carried out using HOT FIREpol universal probe mastermix (Solis Biodyne). 1.5 µL of 5x mastermix, 0.375 µL of TaqMan assay (20x), 3.125 µL of H 2 O and 2.5 µL of 5x diluted cDNA was mixed and run for 95°C 10 min and 40 cycles of 95°C for 15 s and 60°C for 60 s. The data were analysed via GenEx software version 6, reference genes for normalization were identified by Normfinder.
Western blotting
Harvested cells were washed with phosphate-buffered saline (PBS) and lysed in RIPA buffer. Protein concentration was measured via the Pierce BCA protein Assay Kit (Thermo Scientific). 50 µg of total protein was resolved on SDS polyacrylamide gels and blotted onto a nitrocellulose membrane (BioRad). After blocking with 5% non-fat milk (Serva)/ Tris-buffered saline with 0.05% Tween-20 (TBS-T) for 1h, the membrane was incubated overnight in 5% bovine serum albumin/TBS-T with primary antibody against ERα (sc-544, Santa Cruz), PR (8757S, Cell Signaling), GREB1 (HPA024616, Sigma), Cathepsin D (2284S, Cell Signaling), CXCL12 (3740S, Cell Signaling), BMP7 (ab129156, Abcam), β-Actin (5125S, Cell Signaling) diluted 1:1000. Next day, the membrane was washed with TBS-T and probed with secondary antibody conjugated with horseradish peroxidase in 1% milk/TBS-T. The membranes were then washed with TBS-T and incubated with Sirius ECL substrate (Advansta) and chemiluminescence was assessed with LAS4000.
Response of MCF7 cells to estrogen
The cells were washed several times with PBS and 2500 cells per well were seeded in 96-well plate in 100 µL of DMEM media without phenol red (Sigma) supplemented with 10% charcoal stripped fetal bovine serum (Thermo Scientific) and 100U/ml penicillin, 100 µg/ml streptomycin. Cells were incubated with the increasing concentration of 17-β-E 2 for 5 days. Cells were then fixed with 4 % paraformaldehyde in PBS and after paraformaldehyde removal, the cells were stained with 0.05 % crystal violet dye (Sigma). The unbound dye was washed away and the bound dye was dissolved in 1 % SDS. The absorbance was measured at 595 nm using TECAN infinity M200 (TECAN).
In vivo experiments
Female Balb/c nude athymic mice (CAnN.Cg-Foxn1 nu /Crl, Charles River) were implanted subcutaneously with 0.72 mg/90-day-release 17β-E 2 pellet (Innovative Research of America, NE-121) and the following day injected subcutaneously with MCF7 cells inducibly expressing miR-301a or with an EV [29] . Histological classification of carcinomas was performed according to standard diagnostic procedures [30] . Expression of ER and PR was assessed immunohistochemically with the 1% cut-off value for classification of tumors as hormone receptor positive. ERBB2 (OMIM:164870) status was defined as positive in samples with immunohistochemical score 2+ or 3+ confirmed by fluorescence in situ hybridization (FISH) or silver in situ hybridization (SISH) analysis. Clinical characteristics of studied breast carcinoma patients are described in Table 2 .
The expression level of hsa-miR-301a-3p and reference gene was assessed in patient samples by qRT-PCR as described above.
All patients were informed about the study and those who agreed and signed an informed consent participated in the study. The study was approved by the Ethical Commission of the National Institute of Public Health in Prague. The methods were carried out in accordance with guidelines approved by the above Ethical Commission.
Statistics
Results are represented as mean values ± S.E.M from at least three independent experiments. The Student's t-test was used to calculate the difference between groups and P < 0.05 was considered statistically significant.
Results
MiR-301a-3p is highly expressed in the in vitro model of cancer stem-like cells that show inhibition of estrogen signaling
There is increasing evidence that invasive properties of breast cancer rely on reprogramming of cancer cells into cancer stem-like cells [31] , and recent studies suggest that miR-301a-3p contributes to EMT [32] . In order to better characterize the role of miR-301a-3p in cancer stem-like cells, we assessed the expression level of miR-301a-3p by TaqMan assay in our model of cancer stem-like cells based on growing cells as mammospheres in serum-free medium supplemented with EGF and FGF [33] . We generated mammospheres from several ERα positive breast cancer cell lines (ZR-751, MCF7, T-47D and BT474) and compared miR-301a-3p level between spheres and control adherent cells. We also included non-malignant MCF10A cell line of breast origin as a control representing normal breast epithelial cells. We detected significantly higher miR-301a-3p expression in sphere cells compared to control adherent cells in 3 of the tested cell lines (Fig. 1A) . There was no difference between BT-474 control adherent cells and spheres which can be explained by already very high level of miR-301a-3p in adherent BT-474 cells in comparison with other tested adherent cell lines. We further analyzed the estrogen signaling in the adherent cells and mammospheres derived from MCF7 cells. We detected a profound inhibition of ER signaling in spheres, as documented by western blot analysis showing a significant decrease in the ERα protein level and also a decrease in the amount of the ERα-regulated proteins such as Progesterone receptor (PR) and Growth regulation by estrogen in breast cancer 1 (GREB1) expression (Fig. 1B) .
Collectively, our data suggest upregulation of miR-301a-3p in cells growing as mammospheres that represent an in vitro model of cancer stem-like cells. Importantly, these cells show a clear inhibition of estrogen signaling in our model, in accordance with published results [34] .
Functional miR-301a-3p seed sequences are present in the 3´UTR of ESR1 mRNA coding for ERα
In order to assess the importance of the miR-301a-3p in the ERα signaling, we searched for a "seed" sequence within the ESR1 mRNA encoding ERα protein. Using three different publicly available miRNA databases (MiRanda, TargetScan, miRBase) we found that two miR-301a-3p seed sequences are present in the 3'UTR of ESR1 mRNA ( Fig. 2A) .
To verify the prediction that miR-301a-3p negatively regulates ERα expression through binding to the 3'UTR of ESR1 mRNA, we cloned a 4Kb long 3'UTR of the ESR1 mRNA (containing 2 putative miR-301a-3p binding sites) downstream of the Cypridina luciferase gene in a reporter plasmid system. The reporter plasmid was transfected into MCF7 cells together with miR-301a-3p mimic and miR-301a-3p anti-miR and corresponding control mimic and anti-miR. The luciferase activity assay showed a significant reduction in luciferase activity in cells transfected with miR-301a-3p mimic and conversely significant increase of luciferase activity in cells transfected with miR-301a-3p anti-miR (Fig. 2B) . Moreover, we did not detect any changes in luciferase activity when reporter plasmid with deleted miR-301a-3p binding sites was used (Fig.  2B) . To determine which miR-301a-3p binding site is more important for regulation of ERα protein expression, 
we constructed vectors with deleted first, second or both miR-301a-3p binding sites and transfected them into the MCF7, BT474 and T47D cells. We detected an increase in luciferase activity in both deletions meaning both sites can bind miR-301a-3p. However, the first site is more crucial given the fact that the increase in luciferase activity is almost identical when one or both sites are deleted while the deletion of the second motif only leads to a partial increase in luciferase activity (Fig. 2C) .
MiR-301a-3p decreases abundance of ESR1 mRNA and reduces ERα protein level
In order to confirm the biological relevance of miR-301a-3p in the regulation of ESR1, we analyzed the effect of ectopic miR-301a-3p expression on the abundance of ESR1 mRNA and also ERα protein. High expression of miR-301a-3p resulted in a significant decrease in ESR1 mRNA level in MCF7, T47D and BT-474 cells as assessed by qRT-PCR (Fig. 2D ). Also, ERα protein level tested by western blotting was significantly reduced in MCF7 and T47D cells, in BT474 cells the trend was similar but not statistically significant (Fig. 2E) . Our data also show that the effect of downregulation of miR301a-3p by anti-miR was limited and was significant only in BT474 cells which is in line with the fact that these cells express significantly higher endogenous level of miR-301a-3p (Fig. 1A) and the downregulation was the most effective in this particular cell line.
In conclusion, our findings demonstrate that miR-301a-3p recognizes and binds to the 3'UTR of ESR1 mRNA to suppress its translation and mRNA level. 
MiR-301a-3p mimic downregulate the canonical ER pathway as evidenced by inhibition of genes positively regulated by ERα and activation of genes negatively regulated by ERα
ERα is a ligand-activated transcription factor that regulates expression of many target genes [35] . We assessed the expression level of several genes which are positively or negatively regulated by ERα transcription factor in MCF7, T47D and BT474 cells transfected with miR-301a-3p mimic and miR-301a-3p anti-miR and corresponding control RNAs. We found that increased expression of miR-301a-3p leads to a significant decrease in mRNA expression of ERα positively regulated genes as PGRA (Progesterone receptor α), GREB1 (Growth regulation by estrogen in breast cancer 1), CXCL12 (C-x-c motif chemokine ligand 12) or CSTD (Cathepsin D) or to a significant increase in BMP7 (Bone morphogenetic protein 7) which is negatively regulated by ERα (Fig. 3A) . The changes in expression of these genes were also replicated on protein level (Fig. 3B, Fig. 4) .
The effect of anti-miR-301a-3p treatment on ERα signaling pathway was significant only in the BT474 cells. As mentioned earlier, this cells line exhibits high basal expression of miR301a-3p and the effect of anti-miR-301a-3p treatment was thus most evident there, resulting in significant upregulation of the ESR1 mRNA and ERα level (Fig. 2D, E) , accompanied by statistically significant increase in the mRNA transcripts regulated by the ERα such as GREB1, PGRA, CXCL12 reflected in the accumulation of the corresponding proteins (Fig 3A, Fig. 4) .
Similar trend could also be seen in MCF7 and T47D cells but did not reach statistical significance and was weaker compared to BT-474 cells (Fig. 3B, Fig. 4 ). It might be explained by the fact that both MCF7 and T47D cells express relatively low levels of endogenous miR-301a and the effect of anti-miR301a-3P treatment is thus limited compared to the BT474 cells.
In summary, our results show that miR-301a-3p regulates the activity of the ER pathway.
Upregulation of miR301a-3p level in MCF7
cell line leads to a blunted response to 17-β estradiol MCF7 cells transfected with miR-301a-3p mimic and anti-miR and corresponding controls were seeded in 96-well and cell number in estrogenfree medium as well as in the presence of increasing concentrations of 17-β E 2 was measured by crystal violet assay [36] . MCF7 cells transfected with miR-301a-3p mimic show significantly lower number of cells in (Fig. 5A) . We did not detect any statistically significant difference between cells transfected with miR-301-a-3p anti-miR and control anti-miR (Fig.  5B ), probably reflecting low basal level of miR-301a-3p in MCF7 cells. The effect of miR-301a-3p mimic was also recapitulated in doxycycline inducible miR-301a-3p MCF7 cell line. After increasing miR-301a level by doxycycline addition, we observed similar decrease in number of cells in response to 17-β E 2 (Fig. 5C ). No such effect was seen when using MCF7 cells stably transfected with EV (Fig. 5D ).
In conclusion, the decrease of ERα by miR-301a-3p overexpression results in a decreased response to 17-β E 2 .
MCF7 breast cancer cell line inducibly overexpressing miR-301a grow significantly slower in nude mice, show inhibition of ER signaling and exhibit enrichment of the cancer stemlike cells
To determine the role of miR301a-3p in tumor growth, Balb/c nude athymic mice were implanted with slowrelease estradiol pellet and injected subcutaneously with MCF7 cell line expressing miR-301a after induction by doxycycline (Fig. 6A ) or with MCF7 cell line containing an empty vector (EV). Both miR-301a and EV clones exhibited similar growth potential without doxycycline induction in vitro as shown by confluency measurement by JULI FL cell analyzer and the changes in proliferation rates are thus not due to inherent properties of selected clones of MCF7 cells (Fig. 6B) . The mice were given doxycycline diet and tumor growth was monitored twice a week with ultrasound imaging (Vevo770). Results show that the miR-301a overexpressing group exhibits significant inhibition of tumor growth in comparison with control group injected with cells carrying EV only (Fig. 7A) . Both the tumor volume and weight from the miR-301a overexpressing group were significantly decreased in comparison with the control group (Fig. 7B, C) .
Moreover, the overexpression of miR-301a in tumors led to a decrease in expression of ERα and PR proteins, as seen on western blot and also to inhibition of ER signaling measured by qRT-PCR. These results are in line with previous in vitro data and in accordance with the fact that MCF7 cells are dependent on estrogen signaling for their proliferation and once this signaling pathway is inhibited they do not grow (Fig. 7D, E) . Importantly, we have seen a statistically significant upregulation of genes such as CD44, ALDH1 (Aldehyde dehydrogenase 1), ABCG2 (ATP binding cassette transporter subfamily G member 2), VIM (Vimentin), ZEB1, ZEB2 (Zinc finger E-box-binding homeobox 1, 2), HER2 (Erb-b2 receptor tyrosine kinase 2) and VEGFA (Vascular endothelial growth factor A) which are connected with cancer stem-like cell phenotype, EMT and metastasis (Fig. 7F) . Taken together, these data suggest that increased expression of miR-301a decreases the level of ERα which leads to inhibition of tumor growth of the estrogen-dependent MCF7 cell line in vivo, but on the other hand, it seems to induce an enrichment in the cancer stem-like cell population within the tumor.
MiR-301a-3p expression negatively correlates with ESR1 expression in breast cancer patient samples
MiR-301a-3p was found to be a crucial oncogene in human breast cancer acting through multiple pathways and mechanisms to promote tumor growth and metastasis [28, 37, 38] . To understand its role in breast cancer, we assessed the miR-301a-3p level in 111 human patient breast cancer samples clinically divided into four groups according to ER, PR and HER2 expression status, which was further confirmed by TaqMan qRT-PCR (data not shown). We found that expression of miR-301a-3p in ER+/PR+/HER2+ samples was 1.5-times lower when compared with the ER-/PR-/HER2+ patients and 2-times lower in comparison with ER-/PR-/HER2-samples (Fig. 8A) . Similarly, miR-301a-3p was downregulated by 1.9 fold in ER+/PR+/HER2-samples relative to ER-/PR-/HER2+ samples and by 2.5-fold relative to ER-/PR-/HER2-samples (Fig. 8A) . Unlike ER and PR, the expression of HER2 has no statistically significant correlation with the expression of miR-301a-3p in studied samples (Fig. 8A) . On the other hand, a statistically significant negative correlation between the miR301a-3p and ESR1 level was observed (Fig. 8B) .
Collectively, observed results show a negative correlation between the expression of miR-301a-3p and ER/PR status in breast cancer patient samples, suggesting that higher expression of miR-301a-3p is connected with lower expression of ESR1.
Discussion
MiR-301a-3p has been shown as a negative prognostic marker in many human cancers since cells with high level of miR-301a-3p display higher metastatic potential [38, 39] . However, its role in ER-positive breast cancer has not been elucidated yet. Breast cancer is the most frequent malignancy in women worldwide. More than half of the patients are diagnosed with the estrogen positive cancer which has good prognosis and is often treated with the anti-estrogenic drug, tamoxifen. Although the drug is efficient and well tolerated, 30-40 % of patients relapse with metastasis which do not response to endocrine therapy due to loss of ER [40, 41] . The transition from ER-positive to ER-negative breast cancer E R + / P R + / H E R 2 + E R + / P R + / H E R 2 -E R -/ P R -/ H E R 2 + E R -/ P R -/ H E R 2 - Tumor weight (mg) [45] have already been reported to regulate ERα protein expression. In this report, we analyzed the cis regulatory sequences in the 3´UTR of ESR1 gene mRNA and identified 2 seed sequences, which are able to bind miR-301a-3p. We have further generated a reporter vector where Cypridina luciferase gene is coupled to the 3´UTR of ESR1 and demonstrated that deletion of these two sites results in higher expression of the luciferase, thus confirming the role of these two sites in the negative regulation of the ERα protein expression. Interestingly, site deletion showed that the first site closer to the end of translation is a preferred binding site for miR-301a-3p as its deletion resulted in identical phenotype to the deletion of both binding sites. Yet, the deletion of the second site also led to an increase in reporter luciferase expression suggesting that this site can be utilized by miR-301a-3p as well. We showed that miR-301a-3p downregulates ESR1 mRNA and ERα protein level and, more importantly, inhibits the canonical estrogen signaling pathway in MCF7, T47D and BT474 breast cancer cell lines. This leads to lower expression of genes positively regulated by ERα (PGRA, GREB1, CXCL12, CSTD) and to induction of genes negatively regulated by ERα (BMP7). Moreover, we demonstrated that overexpression of miR-301a-3p caused inhibition of proliferation of estrogen-dependent MCF7 cells in vitro and suppressed the growth of miR-301a-3p overexpressing MCF7 tumors in nude mice. These results further confirmed that ESR1 is a direct target of miR-301a-3p in vitro and in vivo and are in line with already published results referring to miRNAs targeting ERα [44, 45] .
We did not detect any significant changes when using miR-301a-3p anti-miR with exception of BT474 cells that express high levels of miR-301a-3p. This suggests that the effect is predominantly caused by the translational inhibition of ESR1 mRNA and could be detected only in cells with higher endogenous miR-301a-3p levels where the anti-miR treatment is more effective. An alternative explanation is that ESR1 mRNA is relatively abundant and contains long 3'UTR with many other regulatory miRNA sites [46] . In that situation, the impact of miR-301a-3p anti-miR could be limited by low expression of miR-301a-3P in comparison with other abundant and non-inhibited regulatory miRNAs as suggested by Androsavich and Chau [47] .
Interestingly, we detected an increase in the expression of HER2 gene in miR-301a-3p overexpressing tumors. Our data are in line with observation that HER2 is upregulated in tamoxifen-resistant MCF7 cells with decreased ERα signaling [48] and also in breast cancer stem-like cells [49] . Apart from HER2, we observed upregulation of other markers related to cancer stem-like cells, EMT and metastatic phenotype such as CD44, ALDH1, ABCG2, VIM, ZEB1, ZEB2 and VEGFA in cells from miR-301a-3p overexpressing tumors. The cancer stem-like cell properties of miR-301a-3p overexpressing cells were further confirmed by analysis of mammospheres, the in vitro model of cancer stem-like cells [33] , which expressed dramatically higher level of miR-301a-3p together with significantly lower ERα protein level, accompanied by inhibition of ERα targets GREB1 and PR. Furthermore, the other ERα-regulating miRNAs such as miR-22, -145 and -206 were not significantly and consistently elevated in sphere samples (data not shown). Given that Shi et al [28] . showed that miR301a-3p renders breast cancer nonresponsive to the anti-estrogenic drug tamoxifen, we hypothesized that upregulation of miR-301a-3p may represent a feasible mechanism contributing to the phenotypical shift of primarily ERα dependent cells toward tumor cells relying on other proliferative signals. More importantly, since miR-301a-3p overexpressing cells acquire properties of cancer stem-like cells, which are highly invasive and resistant to treatment [50] [51] [52] , they might represent the subpopulation that survives endocrine therapy and gives rise to relapsing metastasis.
In order to define whether the expression of miR-301a-3p in the samples of real human breast tumors is correlated with ERα expression, we analyzed primary human breast cancer biopsies and found significantly higher miR-301a-3p level in patient samples that were ER- negative. Similarly, we have detected a significant negative correlation between miR-301a-3p expression and ESR1 expression. Since miR-301a-3p is able to regulate ERα signaling it might serve as a biomarker of breast cancer prognosis and response to endocrine treatment. Our findings are thus in line with findings that higher expression of miR-301a-3p is significantly associated with larger tumor size and lymph node metastases in triple negative breast cancer [37] . Importantly, as miR-301a-3p also regulates other signaling pathways that are important in the progression of breast cancer such as PTEN/Akt or NFκB signaling [28, 38, 53] it can be utilized as a general marker of poor prognosis. In summary, our study provides functional evidence that miR-301a-3p is able to downregulate ER signaling in the ER positive breast cancer cells in vitro as well as in vivo, thus forcing them to become estrogen-independent with high selection pressure to activate alternative survival/pro-proliferative pathways in order to proliferate. The transition of estrogen-dependent cancer into the estrogen-independent cancer is one of the crucial steps in carcinogenesis and together with documented effects of miR-301a-3p on cancer motility and metastasis, our results suggest that miR-301a-3p might be used as a marker of poor patient prognosis and higher chance to become hormone-insensitive and resistant to tamoxifen.
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